[Bradycardia induced by galantamine]. / Bradycardie liée à la galantamine.

An 80-year-old man had to be operated for cutaneous neoplasia. Local anaesthesia with sedation was required. Preoperative examination revealed a pronounced albeit asymptomatic bradycardia. Electrocardiogram showed a complete atrioventricular block. Use of a pacemaker was discussed. Finally, surgery was performed uneventfully after transient reversal of the anticholinesterasic effects of galantamine administered in Alzheimer's disease control over several hours with atropine.

[Programmed left ventricular stimulation in non-sustained ventricular arrhythmias]. / La stimulation ventriculaire programmée dans les arythmies ventricularies non soutenues.

The presence of nonsustained ventricular arrhythmia (NSVA) is an independent factor of sudden rhythmic death. The primary objective of our study was to evaluate the correlation between inducibility during programmed ventricular stimulation (PVS) and the presence of ventricular late potentials, the ejection fraction, the grade of arrhythmia, and the underlying cardiopathy. The secondary objective was to evaluate the interest of PVS in patients with NSVA. Ninety eight patients with NSVA have been tested by PVS and 14 were inducible. During the mean follow up of 24 months, 8 patients died, 3 of them suddenly. A significative statistical correlation was found between ventricular late potentials and inducibility (negative predictive value = 91%; p = 0.03). No correlation was found between the ejection fraction, the grade of arrhythmia, the cardiopathy and inducibility. In patients with ischaemic cardiopathy, PVS has allowed to identify a subgroup of patients with high risk of sudden death. In this subgroup, serial PVS for drug testing has contributed to choose the therapeutic regimen supposed to be more effective for prevention of fatal arrhythmia. Multiple factors explain sudden death, even though the initial treatment has been chosen by electrophysiologic studies. For non inducible patients, empiric treatment is not proven to be reliable, and the best therapeutic regimen is still unidentified, especially in the subgroup of patients with low ejection fraction. In this subgroup, the implantable cardioverter defibrillator vives better protection against sudden rhythmic death.